

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Mumps virus, antibodies, January, 1-2026	35	34	97.1 %


Summary



Summary	AVR success rate
Sample S001	100 %
Sample S002	96.6 %
Sample S003	76.1 %
Average:	90.9 %

Sample S001

Sample S001 success rate



Sample S001 results	Responded	AVR success rate	Count
	Clinical interpretation	100 %	35
	Mumps virus IgG	100 %	35
	Mumps virus IgM	100 %	32
	Total:	100 %	102


Sample S001 Clinical interpretation



- Old immunity or vaccinated
- Does not indicate acute infection
- Laboratory does not give clinical interpretation


Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Old immunity or vaccinated		23		100 %	4	
	Does not indicate acute infection		2		100 %	4	
	Laboratory does not give clinical interpretation		10		-	-	
	Total:		35		100 %		

Sample S001 Mumps virus IgG



■ Positive

Sample S001 Mumps virus IgM




■ Negative

Mumps virus IgG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		35		100 %	2
		bioMerieux VIDAS Mumps IgG		3		
		DiaSorin LIAISON Mumps IgG		20		
		Euroimmun Anti-Mumps Virus IgG ELISA		4		
		In-house EIA		1		
		TestLine Clinical Diagnostics EIA Mumps IgG		1		
		Vircell Mumps VirClia IgG		5		
		Virion/Serion ELISA classic Mumps IgG		1		
	Total:		35		100 %	

Mumps virus IgM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		32		100 %	2
		DiaSorin LIAISON Mumps IgM		19		
		Euroimmun Anti-Mumps Virus IgM ELISA		3		
		In-house EIA		1		
		Microimmune Mumps IgM Capture EIA		1		
		NovaTec NovaLisa Mumps Virus IgM ELISA		1		
		TestLine Clinical Diagnostics EIA Mumps IgM		1		
		Vircell Mumps VirClia IgM		5		
		Virion/Serion ELISA classic Mumps IgM		1		
	Total:		32		100 %	

Sample S002

Sample S002 success rate



Sample S002 results	Responded	AVR success rate	Count
	Clinical interpretation	92 %	35
	Mumps virus IgG	100 %	35
	Mumps virus IgM	100 %	32
	Total:	96.6 %	102


Sample S002 Clinical interpretation



- Acute/recent infection
- Old immunity or vaccinated
- Laboratory does not give clinical interpretation


Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Acute/recent infection		23		100 %	4	
		New sample requested		3	-		-
		Referred to confirmation		4	-		-
		New sample requested and referred to confirmation		1	-		-
	Old immunity or vaccinated		2		0 %	0	
	Laboratory does not give clinical interpretation		10		-	-	
		Referred to confirmation		1	-		-
	Total:		35		92 %		

Sample S002 Mumps virus IgG



■ Positive

Sample S002 Mumps virus IgM




■ Positive

Mumps virus IgG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		35		100 %	2
		bioMerieux VIDAS Mumps IgG		3		
		DiaSorin LIAISON Mumps IgG		20		
		Euroimmun Anti-Mumps Virus IgG ELISA		4		
		In-house EIA		1		
		TestLine Clinical Diagnostics EIA Mumps IgG		1		
		Vircell Mumps VirClia IgG		5		
		Virion/Serion ELISA classic Mumps IgG		1		
	Total:		35		100 %	

Mumps virus IgM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		32		100 %	2
		DiaSorin LIAISON Mumps IgM		19		
		Euroimmun Anti-Mumps Virus IgM ELISA		3		
		In-house EIA		1		
		Microimmune Mumps IgM Capture EIA		1		
		NovaTec NovaLisa Mumps Virus IgM ELISA		1		
		TestLine Clinical Diagnostics EIA Mumps IgM		1		
		Vircell Mumps VirClia IgM		5		
		Virion/Serion ELISA classic Mumps IgM		1		
	Total:		32		100 %	


Sample S003

Sample S003 success rate



Sample S003 results	Responded	AVR success rate	Count
	Clinical interpretation	68 %	35
	Mumps virus IgG	100 %	35
	Mumps virus IgM	62.5 %	32
	Total:	76.1 %	102


Sample S003 Clinical interpretation



- Acute/recent infection
- Does not indicate acute infection
- Old immunity or vaccinated
- Laboratory does not give clinical interpretation


Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Acute/recent infection		17		100 %	4	
		New sample requested and referred to confirmation		1	-		-
		New sample requested		2	-		-
		Referred to confirmation		3	-		-
	Does not indicate acute infection		1		0 %	0	
		New sample requested		1	-		-
	Old immunity or vaccinated		7		0 %	0	
	Laboratory does not give clinical interpretation		10		-	-	
		Referred to confirmation		1	-		-
	Total:		35		68 %		

Sample S003 Mumps virus IgG



■ Positive

Sample S003 Mumps virus IgM



■ Negative ■ Borderline ■ Positive

Mumps virus IgG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		35		100 %	2
		bioMerieux VIDAS Mumps IgG		3		
		DiaSorin LIAISON Mumps IgG		20		
		Euroimmun Anti-Mumps Virus IgG ELISA		4		
		In-house EIA		1		
		TestLine Clinical Diagnostics EIA Mumps IgG		1		
		Viricell Mumps VirClia IgG		5		
		Virion/Serion ELISA classic Mumps IgG		1		
	Total:		35		100 %	

Mumps virus IgM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		5		0 %	0
		DiaSorin LIAISON Mumps IgM		4		
		In-house EIA		1		
	Borderline		7		0 %	0
		DiaSorin LIAISON Mumps IgM		7		
	Positive		20		100 %	2
		DiaSorin LIAISON Mumps IgM		8		
		Euroimmun Anti-Mumps Virus IgM ELISA		3		
		Microimmune Mumps IgM Capture EIA		1		
		NovaTec NovaLisa Mumps Virus IgM ELISA		1		
		TestLine Clinical Diagnostics EIA Mumps IgM		1		
		Viricell Mumps VirClia IgM		5		
		Virion/Serion ELISA classic Mumps IgM		1		
	Total:		32		62.5 %	

Report Info**PARTICIPANTS**

Altogether 35 laboratories from 13 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported. The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates. The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.